Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Lancet Diabetes Endocrinol 2022 Jul 29;[EPub Ahead of Print], N Inagaki, M Takeuchi, T Oura, T Imaoka, Y SeinoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.